Janssen

NICE refuses to recommend Janssen’s Zytiga for prostate cancer

Wednesday, February 8, 2012 09:58 AM

The National Institute for Health and Clinical Excellence (NICE), the U.K. healthcare guidance body, has issued new draft guidance not recommending the use of Zytiga (abiraterone), developed by Janssen, in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer that has progressed on or after docetaxel-containing therapy.

More... »

Alzheimer's Challenge 2012 seeks new tools to improve Alzheimer's care

Thursday, January 26, 2012 10:47 AM

South San Francisco-based Janssen Alzheimer Immunotherapy, together with Pfizer—its collaborator on the Alzheimer's Immunotherapy Program (AIP)—and the Geoffrey Beene Gives Back Alzheimer's Initiative, have introduced the Alzheimer's Challenge 2012, calling for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer's disease.

More... »

Forma and Janssen to collaborate on cancer drug

Wednesday, January 11, 2012 11:19 AM

Forma Therapeutics has formed an exclusive alliance with Janssen Biotech (a subsidiary of Johnson & Johnson), in which the pair will collaborate on discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

More... »

Metamark, Janssen ink $365 million research agreement

Tuesday, December 20, 2011 01:12 PM

Metamark Genetics has entered into a research, collaboration, and license agreement with Janssen Biotech. The agreement is based on Metamark's discovery platform for the identification and characterization of specific proprietary cancer targets demonstrated to play a causal role in promoting tumor progression and spread. The collaboration will focus on the evaluation and validation of several of Metamark's Prognosis Determinants. Upon selection of the targets, Janssen Biotech will receive a limited exclusive license under Metamark's intellectual property and know-how and will thereafter be responsible for the discovery, development, and commercialization of therapeutic inhibitors targeting the specific Prognosis Determinants.

More... »

Janssen, Pharmacyclics collaborate to develop anti-cancer drug

Friday, December 9, 2011 07:56 AM

Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765. A number of phase I and II studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

More... »

Molecular Partners expands research collaboration with Janssen Biotech

Thursday, December 8, 2011 12:17 PM

Molecular Partners has entered into a strategic research collaboration and option agreement with Janssen Biotech to research, discover and develop DARPin products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins, to address diseases where continued unmet needs for effective treatment options continue to exist.

More... »

Bristol Myers enters clinical collaboration with Tibotec

Friday, December 2, 2011 11:35 AM

Bristol-Myers Squibb has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical companies, to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals' investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV).

More... »

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

FDA approves REMICADER for pediatric UC

Tuesday, September 27, 2011 12:02 PM

FDA has approved Janssen Biotech’s REMICADER (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.  This marks the 16th approval of REMICADER in the U.S. and the seventh for the anti-tumor necrosis factor (TNF)-alpha in the treatment of inflammatory bowel disease (IBD) spanning adult and pediatric Crohn's disease and adult and pediatric UC.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with symptoms of IBD.

More... »

EMA recommends INCIVO for hepatitis C virus

Friday, July 29, 2011 10:25 AM

Tibotec Virco-Virology BVBA, part of Janssen Pharmaceutical, reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of INCIVO (telaprevir), a direct acting antiviral (DAA) for the treatment of chronic genotype-1 hepatitis C virus (HCV), in combination with pegylated-interferon and ribavirin, the previously accepted standard of care.

More... »